Clinical trial
ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute…
NCT00300196 · Neurobiological Technologies, Industry · Terminated
Key facts
| NCT number | NCT00300196 |
|---|---|
| Title | ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke |
| Official title | ASP II (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute Ischemic Stroke |
| Lead sponsor | Neurobiological Technologies, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Stroke, Cerebral Ischemia, Brain Infarction |
| Intervention type | Biological, Drug |
| Interventions | Ancrod (Viprinex), Placebo |
| Enrollment | 311 |
| Start date | Mar 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Mar 8, 2006 |
| Last update posted | Jan 12, 2010 |
| Countries | Australia, Austria, Czechia, Israel, New Zealand, Poland, Russia, Slovakia, South Africa, Switzerland, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: